Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujata Patil

Showing results (151-160 of 230) with videos related to

Pageof 23
Sort By:
The Journal of Clinical Investigation|November 11, 2025
Neutrophil to lymphocyte ratio varies in magnitude and biomarker utility based on patient demographicsWilliam Ang, Travis D Kerr, Ananya Kodiboyena, et al.
Clinical Breast Cancer|January 5, 2016
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 InhibitorsKomal Jhaveri, Sarat Chandarlapaty, Neil Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 24, 2018
Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal ExcisionFelipe Quezada-Diaz, Rosa M Jimenez-Rodriguez, Emmanouil P Pappou, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 3, 2020
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinomaRaza Syed Hoda, Edi Brogi, Carlos Henrique Dos Anjos, et al.
Leukemia & Lymphoma|September 20, 2013
Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemiaJane Houldsworth, Asha Guttapalli, Venkata Thodima, et al.
The Journal of Urology|May 11, 2023
Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive NephrectomyStephen W Reese, Sari Khaleel, Andrew Silagy, et al.
Frontiers in Oncology|November 10, 2022
Quality of life and function after rectal cancer surgery with and without sphincter preservationEmmanouil P Pappou, Larissa K Temple, Sujata Patil, et al.
Clinical Genitourinary Cancer|June 2, 2019
Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment OutcomesYasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Breast Cancer Research : BCR|August 3, 2017
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerKomal Jhaveri, Rui Wang, Eleonora Teplinsky, et al.
Pageof 23

Showing results (151-160 of 230) with videos related to

Sort By:
Pageof 23
The Journal of Clinical Investigation|November 11, 2025
Neutrophil to lymphocyte ratio varies in magnitude and biomarker utility based on patient demographicsWilliam Ang, Travis D Kerr, Ananya Kodiboyena, et al.
Clinical Breast Cancer|January 5, 2016
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 InhibitorsKomal Jhaveri, Sarat Chandarlapaty, Neil Iyengar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 24, 2018
Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal ExcisionFelipe Quezada-Diaz, Rosa M Jimenez-Rodriguez, Emmanouil P Pappou, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 3, 2020
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinomaRaza Syed Hoda, Edi Brogi, Carlos Henrique Dos Anjos, et al.
Leukemia & Lymphoma|September 20, 2013
Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemiaJane Houldsworth, Asha Guttapalli, Venkata Thodima, et al.
The Journal of Urology|May 11, 2023
Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive NephrectomyStephen W Reese, Sari Khaleel, Andrew Silagy, et al.
Frontiers in Oncology|November 10, 2022
Quality of life and function after rectal cancer surgery with and without sphincter preservationEmmanouil P Pappou, Larissa K Temple, Sujata Patil, et al.
Clinical Genitourinary Cancer|June 2, 2019
Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment OutcomesYasser Ged, Ying-Bei Chen, Andrea Knezevic, et al.
Breast Cancer Research : BCR|August 3, 2017
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerKomal Jhaveri, Rui Wang, Eleonora Teplinsky, et al.
Pageof 23